MRL828
MRL828 is a heterobifunctional molecule that targets aggregated tau protein. As an autophagy-targeting chimera (ATTEC), MRL828 selectively labels aggregated tau protein for clearance via the autophagy (autophagy)-lysosome pathway. The activity of MRL828 depends on autophagosomes rather than lysosomes, and it induces autophagosome-dependent secretion. MRL828 acts as an intracellular aggregate inhibitor and a secretory autophagy inducer, reducing intracellular levels of aggregated tau protein through autophagosome-dependent secretory autophagy instead of lysosomal degradation. MRL828 can be used in the research of neurodegenerative diseases such as Alzheimer's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3115333-82-6
- Formule: C46H51FN14O5S
- Masse moléculaire:931.05
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
Tau aggregates 50 nM (DC50) |
In Vitro
The reduction of aggregated tau induced by MRL828 (1 μM; 24-48 h) in tau aggregation-induced CHO T-REx P301L cells depends on p62 and VPS34, components of the autophagy pathway[1].
MRL828 (1 μM, 24-48 h) still reduces tau aggregates in the presence of Bafilomycin A1 (HY-100558, 25 nM) or Hydroxychloroquine (HY-W031727, 15 μM), and does not increase the colocalization of MC1-positive tau puncta with the lysosomal marker LAMP2 at 24 h, indicating that its mechanism of action is independent of lysosomes.[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:tau aggregation-induced CHO T-REx P301L cells
-
Concentration:1 μM (MRL828); 100 nM (Bafilomycin A1 for LC3-II analysis); 25 nM (Bafilomycin A1 for DQ-BSA imaging)
-
Incubation Time:MRL828 44 h followed by Bafilomycin A1 cotreatment for 4 h for LC3-II analysis; MRL828 or Bafilomycin A1 48 h, with DQ-BSA added 6 h before the end of treatment
-
Result:Did not alter LC3-II accumulation, and showed the same Bafilomycin A1-induced LC3-II accumulation as vehicle-treated cells.
Did not impair DQ-BSA-based lysosomal proteolysis, indicating no change in lysosomal degradation capacity.
Chemical Information
-
CAS No. 3115333-82-6
-
Masse moléculaire 931.05
-
Formule C46H51FN14O5S
-
SMILES
O=C(NCCCOCCCCOCCCNC1=NC=C(C#CC2=CC=C(C3=CN4C=C(CO)C=CC4=N3)N=C2)C=N1)[C@@H](NC(C)=O)CSC5=NC6=C(N)N=C(N)N=C6N5CC7=CC=C(F)C=C7
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MRL828 Related Classifications
HY-176130 Related Classifications
Powered by Bioz